CJC-1295 (no DAC)vsCJC-1295 + Ipamorelin

CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (at positions 2, 8, 15, and 27) have been made to increase resistance to enzymatic degradation while preserving full biological activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary.

When CJC-1295 binds the GHRH receptor, it activates the Gs alpha subunit, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors that drive GH gene expression and secretion. Importantly, this mechanism preserves the natural pulsatile pattern of GH release because it works within the existing hypothalamic-pituitary feedback loop — somatostatin still provides inhibitory regulation between pulses.

The key advantage of the no-DAC version over the DAC version is this preservation of pulsatility. Because its half-life is approximately 30 minutes, it produces a discrete GH pulse that rises and falls naturally, mimicking the body's own secretory pattern. This pulsatile pattern is believed to be physiologically superior to sustained elevation because GH receptor sensitivity is maintained between pulses, and the liver's IGF-1 production response is optimized by intermittent rather than continuous GH stimulation. This is why CJC-1295 (no DAC) is often preferred by practitioners despite requiring more frequent dosing.

The CJC-1295 + Ipamorelin combination exploits the synergistic interaction between two distinct signaling pathways on pituitary somatotroph cells. CJC-1295 (Mod GRF 1-29) activates the GHRH receptor, a Gs-coupled GPCR that stimulates adenylyl cyclase, raising intracellular cAMP and activating PKA. Ipamorelin activates the ghrelin/GHS-R1a receptor, a Gq/11-coupled GPCR that stimulates phospholipase C, generating IP3 and DAG, raising intracellular calcium and activating protein kinase C.

These two pathways converge on the final common pathway of GH vesicle exocytosis but through complementary mechanisms. cAMP/PKA signaling (from CJC-1295) primes GH gene transcription and vesicle loading, while calcium/PKC signaling (from Ipamorelin) triggers the actual calcium-dependent exocytosis of GH-containing secretory granules. When both pathways are activated simultaneously, the resulting GH pulse is significantly larger than what either peptide produces alone — studies suggest the combined GH output can be 3-5 times greater than either agent in isolation.

Additionally, Ipamorelin's hypothalamic effects complement CJC-1295's direct pituitary action. At the hypothalamic level, ghrelin receptor agonists suppress somatostatin release from periventricular neurons, removing the inhibitory brake on GH secretion. This creates a permissive window during which CJC-1295's GHRH-like stimulation of somatotrophs is maximally effective. Importantly, both peptides preserve the natural pulsatile pattern of GH release — somatostatin feedback still operates between pulses, maintaining the physiological pulse spacing that is important for target tissue sensitivity. The combination's selectivity profile is also favorable: Ipamorelin's selectivity avoids the cortisol and prolactin elevation seen with older GHRPs, while CJC-1295's 30-minute half-life avoids the sustained GH elevation of the DAC version. This makes CJC/Ipa the most widely prescribed GH peptide stack in anti-aging medicine.